<DOC>
	<DOCNO>NCT00002558</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel , ifosfamide , carboplatin , etoposide work different way stop growth tumor cell , either kill stop divide . Giving chemotherapy peripheral stem cell transplant may allow chemotherapy give tumor cell kill . The design trial phase I/II trial sequential accelerate chemotherapy cycle taxol/ifosfamide carboplatin/etoposide administer G-CSF PBSC support . PURPOSE : The purpose study determine effect intensive sequence chemotherapy drug patient metastatic germ cell cancer . All chemotherapy drug know active disease .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Treating Patients With Germ Cell Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety paclitaxel ifosfamide follow carboplatin etoposide stem cell support patient unfavorable germ cell tumor unfavorable prognostic factor resistance cisplatin . - Determine efficacy regimen salvage therapy patient . - Escalate dose carboplatin base target area concentration time curve renal function , determine pharmacokinetics carboplatin select patient . - Determine qualitative effect paclitaxel ifosfamide hematopoietic progenitor patient . OUTLINE : This dose escalation study carboplatin . - Part A : Patients receive paclitaxel IV continuously day 1 ifosfamide IV 4 hour day 2-4 . Autologous peripheral blood stem cell ( PBSC ) harvest day 11-13 . Filgrastim ( G-CSF ) administer subcutaneously ( SC ) twice daily begin 6 hour completion paclitaxel ifosfamide infusion continue last day leukapheresis . Treatment continue every 2 week 2 course absence disease progression unacceptable toxicity . Before begin first course chemotherapy , autologous bone marrow ( ABM ) harvest , possible , case insufficient peripheral blood stem cell ( PBSC ) harvest . Patients unable undergo harvest ABM first course chemotherapy undergo harvest ABM begin second course chemotherapy . - Part B : Beginning 2 week completion regimen A , patient receive etoposide IV 2 hour carboplatin IV 1 hour day 1-3 . PBSC reinfused day 5 . G-CSF administer SC twice daily begin 6 hour completion etoposide carboplatin infusion continue blood count recover . G-CSF hold morning PBSC transplantation restart begin 6 hour completion PBSC transplantation . Treatment continue every 2 week 3 course absence disease progression unacceptable toxicity . Patients insufficient PBSC second course receive PBSC combine ABM . Patients insufficient PBSC third course receive ABM . During second part , cohorts 3-6 patient receive escalate dos carboplatin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 3 6 patient experience dose-limiting toxicity . After completion part A B , patient may undergo resection residual mass .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>Inclusion criterion : Male/Female histologically confirm GCT review Department Pathology center . Patients advance GCT , include patient : measurable evaluable disease , patient elevate serum tumor marker ( AFP and/or HCG ) , patient know residual disease postchemotherapy surgery . Eligible patient must establish clinical resistance cisplatin failure achieve durable CR cisplatinbased regimen . Prior treatment limit ≤ 6 prior cycle ( ≤ four cycle prefer ) cisplatin . ( GROUP A ) Prior therapy &gt; 6 cycle cisplatin . ( GROUP B ) Therapy must discontinue least 3 week entry onto protocol . Patients must one unfavorable prognostic factor achieve CR cisplatinbased salvage therapy . These : Extragonadal primary site . Testis/ovarian primary site best response IR firstline therapy , partial response normal tumor marker six month less duration . Prior treatment ifosfamidecontaining therapy General medical condition sufficient allow general anesthesia time pheresis catheter placement . Patients must negative serology Human Immunodeficiency Virus . Laboratory criterion protocol entry : WBC ≥ 3000/ul Platelets 3 100,000/ul Cr Clearance &gt; 50 cc/min* * ( unless renal dysfunction due tumor obstruct ureter case eligibility determine Principal Investigator ) . Age ≥ 15 year . Signed informed consent . Presence active infection Concurrent treatment chemotherapy Inability comply treatment protocol undergo specify followup test safety effectiveness . Prior highdose therapy AuBMT . Patients must recover recent surgery .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>recurrent malignant testicular germ cell tumor</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>extragonadal germ cell tumor</keyword>
</DOC>